Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US (REMAIN)

This study has been completed.
Sponsor:
Collaborator:
i3 Innovus
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00795093
First received: November 20, 2008
Last updated: May 10, 2010
Last verified: May 2010
  Purpose

The purpose of this study is to describe common treatment pathways, to collect health care utilization data and to assess symptom load as well as impact of symptoms on daily life in GERD patients who are partial-responders to PPI treatment.


Condition
Gastroesophageal Reflux Disease (GERD)

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Quality of life, productivity loss, frequency and severity of GERD symptoms, health care resource use [ Time Frame: Collected at enrollment visit and at 3 and 6 month follow-up. (Health care resource use is at enrollment visit collected retrospectively 6 months) ] [ Designated as safety issue: No ]
  • Utility values [ Time Frame: Collected at enrollment visit and at 6 month follow-up. ] [ Designated as safety issue: No ]

Enrollment: 552
Study Start Date: November 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
552 GERD patients, partial responders to PPI treatment

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with Gastroesophageal Reflux Disease (GERD) classified as partial responders to proton pump inhibitors (PPIs).

Criteria

Inclusion Criteria:

  • At least 6 month history of GERD symptoms
  • Treated with unchanged optimized PPI treatment for any GERD indication during a consecutive 4 week period
  • Remaining GERD symptoms despite optimized PPI treatment
  • Able to read and write in US English, and able to comply with study requirements

Exclusion Criteria:

  • Patients that have not experienced any GERD symptom improvement at all during PPI treatment
  • Involvement in the planning or conduct of the study
  • Involvement in any other observational study or in any clinical study at the time of this study or during the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00795093

  Hide Study Locations
Locations
United States, Alabama
Research Site
Leeds, Alabama, United States
United States, Arizona
Research Site
Pheonix, Arizona, United States
Research Site
Tucson, Arizona, United States
United States, California
Research Site
Concord, California, United States
Research Site
Lancaster, California, United States
Research Site
Los Banos, California, United States
Research Site
Solana Beach, California, United States
United States, Delaware
Research Site
Newark, Delaware, United States
United States, Florida
Research Site
Altamonte Springs, Florida, United States
Research Site
Cocoa, Florida, United States
Research Site
Defuniak Springs, Florida, United States
Research Site
Largo, Florida, United States
Research Site
Maitland, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Naples, Florida, United States
Research Site
Ocala, Florida, United States
Research Site
Orlando, Florida, United States
Research Site
Palm Harbor, Florida, United States
Research Site
Peonia, Florida, United States
Research Site
Tampa, Florida, United States
United States, Georgia
Research Site
Columbus, Georgia, United States
Research Site
Roswell, Georgia, United States
Research Site
Royston, Georgia, United States
Research Site
Snellville, Georgia, United States
United States, Illinois
Research Site
Belleville, Illinois, United States
United States, Indiana
Research Site
Mishawaka, Indiana, United States
United States, Louisiana
Research Site
Metaire, Louisiana, United States
United States, Maryland
Research Site
Prince Frederick, Maryland, United States
Research Site
Towson, Maryland, United States
United States, Missouri
Research Site
Florissant, Missouri, United States
Research Site
Jefferson City, Missouri, United States
United States, New Jersey
Research Site
Atco, New Jersey, United States
Research Site
Fair Lawn, New Jersey, United States
United States, North Carolina
Research Site
Cary, North Carolina, United States
Research Site
Elkin, North Carolina, United States
Research Site
New Bern, North Carolina, United States
Research Site
Stanley, North Carolina, United States
Research Site
Statesville, North Carolina, United States
United States, Ohio
Research Site
Beachwood, Ohio, United States
Research Site
Dayton, Ohio, United States
Research Site
Vandalia, Ohio, United States
United States, Pennsylvania
Research Site
Aliquippa, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
United States, Rhode Island
Research Site
Warwick, Rhode Island, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
United States, Tennessee
Research Site
Athens, Tennessee, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Irving, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Marcos, Texas, United States
Research Site
Southlake, Texas, United States
United States, Utah
Research Site
West Jordan, Utah, United States
Sponsors and Collaborators
AstraZeneca
i3 Innovus
Investigators
Principal Investigator: Meg Good i3 Innovus
Study Director: Marie Sundin AstraZeneca
  More Information

No publications provided

Responsible Party: Debra Silberg, MD PhD, Medical Science Director, Clinical Research, AstraZeneca R&D
ClinicalTrials.gov Identifier: NCT00795093     History of Changes
Other Study ID Numbers: D9120N00005
Study First Received: November 20, 2008
Last Updated: May 10, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by AstraZeneca:
GERD
PPI
partial responders

Additional relevant MeSH terms:
Gastroesophageal Reflux
Deglutition Disorders
Digestive System Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 29, 2014